Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tacabrutideg in Participants With Moderate and Severe Hepatic Impairment

NCT07856004 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT07856004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07856004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tacabrutideg in Participants With Moderate and Severe Hepatic Impairment
Lead sponsor
BeOne Medicines
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 22, 2026
Completion date
July 31, 2027
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult participants, hepatic impairment